Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CNS

Set Alert for CNS

Bionomics Posts Positive Data In PTSD With Struggling Anxiety Drug

After failing in a Phase II trial in social anxiety disorder, Bionomics thinks mid-stage data for BNC210 in post-traumatic stress disorder may now position the drug as a novel therapy for PTSD.

Clinical Trials Business Strategies

Achieve Life Sciences Believes It Has The New Chantix

Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market. 

Clinical Trials Neurology

Biopharma’s Must-Know Q4 Catalysts

Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too. 

Clinical Trials Companies

Takeda Uses AcuraStem Deal To Bolster Neuro Pipeline, Move Into ALS

Deal Snapshot: Looking to add to its neuroscience pipeline, Takeda acquires rights to the antisense candidate AS-202 from AcuraStem for development as a potential amyotrophic lateral sclerosis therapy.

Deals Business Strategies

Relmada Hopes Open-Label Efficacy, Safety Bolster Profile Of Depression Candidate

With a pair of Phase III setbacks due to high placebo response, Relmada reports positive efficacy and safety data from an open-label trial while awaiting data from two ongoing pivotal studies for REL-1017, an NMDA antagonist.

Clinical Trials Research & Development

Seelos Forges Ahead With SLS-002, Says Primary Endpoint Miss Due To Underpowered Trial

The company blamed lack of funding for incomplete enrollment of the Phase II study in acute suicidal ideation and behavior in major depressive disorder, saying it would have reached statistical significance had it fully enrolled.

Clinical Trials Business Strategies

Eisai Digital Venture Theoria Plans Dementia Data Insights

A new digital health venture set up by Eisai plans to start operations in Japan from April 2024 with services related to cognitive impairment and dementia, in line with the Japanese firm's therapeutic advances in this area.

Japan Digital Health

BioAge Looks To Tackle Diseases Of Aging, Starting With Muscle Loss

Emerging Company Profile: BioAge has Phase Ib proof-of-concept data in age-related muscle loss and is gearing up for its first Phase II study, but will need fresh cash or a partner for a potential weight loss-related muscle loss study.

Companies Clinical Trials

Korea's AriBio Progresses Phase III Program For Oral Alzheimer's Contender

South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.

Clinical Trials Neurology

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.

Commercial Executive Changes

Neurocrine’s Crinecerfont Draws Cautious Optimism On Clinical Meaningfulness

The biotech plans to file for approval for congenital adrenal hyperplasia (CAH) next year and is now looking ahead to a pediatric study, which may pose lower risk.

Clinical Trials Rare Diseases

AMO Pharma Shows Weakness In Myotonic Dystrophy

A pivotal miss leaves the company more reliant on earlier-stage pipeline programs as it talks to regulators about the path forward for its lead product.

Clinical Trials Neurology
See All
UsernamePublicRestriction

Register